| Quantity | 5 mg, 10 mg | 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg | 100 mg, 250 mg, 500 mg, 1 g | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Hel 13-5 is a monomeric synthetic peptide based on the N-terminal segment of human SP-B. Hel 13-5 mainly is a-helical and consists of 13 hydrophobic and 5 hydrophilic amino acid residues. Hel 13-5 can be used in combination with phospholipids for developing pulmonary surfactant model systems[1][2] | CGGRGD TFA, a RGD derivative with cysteine as its N-terminal[1] | Hexapeptide-11 is an anti-aging peptide that can protect fibroblasts from premature cell senescence mediated by oxidative stress. Hexapeptide-11 is also a potential stimulator of hyaluronic acid in keratinocytes, and can enhance skin barrier function by upregulating the expression of HAS2 and EGR3, Hexapeptide-11 is an anti-aging peptide that can protect fibroblasts from premature cell senescence mediated by oxidative stress. Hexapeptide-11 is also a potential stimulator of hyaluronic acid in keratinocytes, and can enhance skin barrier function by upregulating the expression of HAS2 and EGR3, and downregulating the expression of HYAL2. Hexapeptide-11 can also improve skin elasticity[1][2][3]... Read More | Human milk lysozyme is the lysozyme found in human milk. Human milk lysozyme is thought to be a key defense factor in protecting the gastrointestinal tract of newborns against bacterial infection[1] | RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities[1][2]... Read More |